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Abstract
The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some
patients gradually develop resistance to imatinib, resulting in therapeutic failure. Metabonomic and genomic profiling of
patients’ responses to drug interventions can provide novel information about the in vivo metabolism of low-molecular-
weight compounds and extend our insight into the mechanism of drug resistance. Based on a multi-platform of high-
throughput metabonomics, SNP array analysis, karyotype and mutation, the metabolic phenotypes and genomic
polymorphisms of CML patients and their diverse responses to imatinib were characterized. The untreated CML patients
(UCML) showed different metabolic patterns from those of healthy controls, and the discriminatory metabolites suggested
the perturbed metabolism of the urea cycle, tricarboxylic acid cycle, lipid metabolism, and amino acid turnover in UCML.
After imatinib treatment, patients sensitive to imatinib (SCML) and patients resistant to imatinib (RCML) had similar
metabolic phenotypes to those of healthy controls and UCML, respectively. SCML showed a significant metabolic response
to imatinib, with marked restoration of the perturbed metabolism. Most of the metabolites characterizing CML were
adjusted to normal levels, including the intermediates of the urea cycle and tricarboxylic acid cycle (TCA). In contrast,
neither cytogenetic nor metabonomic analysis indicated any positive response to imatinib in RCML. We report for the first
time the associated genetic and metabonomic responses of CML patients to imatinib and show that the perturbed in vivo
metabolism of UCML is independent of imatinib treatment in resistant patients. Thus, metabonomics can potentially
characterize patients’ sensitivity or resistance to drug intervention.
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Introduction
In the postgenomic era, the complementary use of high-
throughput analytical technologies (such as genomics, proteomics,
and metabonomics) in biological systems has revolutionized
biological investigations. Genomic variation appears to be an
important factor that can enhance or reduce the risk of developing
a disease, depending on the specific genetic or epigenetic pathway
involved [1,2]. It has been demonstrated that chronic myeloid
leukemia (CML) involves a translocation between chromosomes 9
and 22, which results in the expression of the BCR–ABL fusion
protein. The tyrosine kinase activity of oncogenic ABL proteins is
known to be essential for its transforming activity [3]. Imatinib
mesylate (imatinib) is a small molecular inhibitor of the tyrosine
kinase activity of the BCR–ABL fusion protein, and is now a
frontline therapy for CML [4]. Despite imatinib’s striking efficacy,
resistance develops over time in many patients, and is more
common in patients with advanced-stage CML [5]. Routine
cytogenetic analysis and molecular methodologies can identify
resistance or sensitivity to imatinib in CML patients, and are
considered the gold standards for evaluating the potential response
to imatinib in clinical practice [6,7]. However, the two methods do
not provide further molecular information about the in vivo
metabolic perturbation involved, which may clarify the mecha-
nism of resistance, or allow us to metabonomically characterize
sensitive CML patients (SCML) and resistant CML patients
(RCML). Our understanding of the biological functions involved
would benefit greatly from an understanding of the metabolic
network, including quantitative measurements of different types of
compounds (such as proteins and metabolites) and various
biochemical processes (such as gene expression) made in parallel,
and preferably combined with other classical phenotypic analyses
[8]. Although many researchers have monitored the response to
imatinib in CML patients using molecular methodologies and
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investigation has been made of the responses of CML patients to
imatinib.
Metabonomics is defined as the quantitative measurement of
endogenous low-molecular-weight compounds that reflect the
metabolic responses of living systems to diverse stimuli [2,11,12].
The metabolic phenotype constitutes the endpoint of various
metabolic responses and is influenced by genomic and proteomic
factors. It can be used to identify early signals/biomarkers of
cellular abnormalities that occur before the appearance of gross
phenotypic changes [1]. Metabonomics can be used as a
complementary tool, providing information about the metabolic
network that cannot be obtained directly from the genotype, gene
expression profiles, or even the proteome of an individual [2]. It
has been successfully applied to biomedical sciences [2,11,13–9],
and shows promising applications in the exploration of diseases
and in the development of personalized drug treatments [2,18,19].
Metabonomics can potentially be applied to the discovery of
tumor metabolic pathways, the investigation of metabolic
responses to treatments [20], and the identification of tumor
biomarkers of these responses [11,12,15]. In this study, using a
metabonomic platform we developed based on gas chromatogra-
phy/time-of-flight mass spectrometry (GC/TOFMS) and data
analysis techniques [21,22], we integrated metabonomic data with
cytogenetic and molecular analyses to profile the metabolic
phenotypes of CML patients and differentiate their metabolic
responses to imatinib.
Results
CML patients
Fifty-nine patients were enrolled in the study: 53 with chronic-
phase (CP) CML and 6 with blast crisis (BC). Two BC patients had
a complex karyotype. Of these 59 patients, 26 were untreated
(UCML). The other 33 CML patients were treated with imatinib
at daily doses of 300–800 mg, and 19 achieved complete
cytogenetic remission (0% Philadelphia chromosome; ‘‘sensitive
CML’’, SCML), whereas 14 patients were resistant to imatinib
(RCML; Table 1). Seven of the RCML patients displayed primary
RCML and seven displayed secondary RCML. Chronic-phase,
blast crisis, and primary cytogenetic resistance were determined as
described in a recent study [5]. The healthy volunteers included
nine men and nine women, with a median age of 35.2 years.
Mutation of the ABL kinase domain in RCML patients
In the 14 resistant patients analyzed, ABL kinase domain
mutations were detected in only 1 BC patient, who presented with
three types of amino acid changes: L232P, F336L, and C349R.
High-density single nucleotide polymorphism (SNP) array
analysis of CML patients
After exclusion of genomic copy number polymorphisms by
comparison of the data with recorded copy number polymor-
phisms in the UCSC Genome Browser (http://genome.ucsc.edu/)
databases,a total of 44 deletions, 2 duplication, and 7 regions of
loss of heterozygosity (LOH) were identified by SNP array analysis
in 9 CML samples, i.e., 1 SCML, 4 primary RCML and 4
secondary RCML (Table 2). In addition to sex chromosome, four
of 6 CP RCML patients did not show other abnormal genome.
Moreover, Cryptic deletions on chromosome X and Y were found
in patients with CP-CML both in SCML and RCML.
Acquired GC/TOFMS data and the identification of
compounds
A typical total-ion-current chromatogram showed several
hundred peaks in a single analysis (Figure 1). After deconvolution
of the chromatograms, much quantitative and qualitative
information was obtained. In general, a total of 186 non-targeted
peaks/metabolites were detected, and a data matrix of 186677 (77
observations/sample) was constructed. Altogether, 22 peaks were
excluded from further data processing because they were not
detected in the normal control and might have been artifacts
derived from drug metabolites or other sources. In consequence,
96.97% of the peak areas were validated, with data missing for 382
peak areas (these GC/TOFMS responses are very low) in the
whole data matrix of 164677. By comparison with authentic
reference standards or reference compounds in available libraries,
72 compounds were identified, including amino acids, organic
acids, amines, saccharides, lipids, fatty acids, etc. (Table S1).
Metabolic patterns of UCML, SCML, and RCML
For an overview of the dataset, an unsupervised principal
components analysis (PCA) was applied to the data. Three serious
outliers were identified, one each from the healthy control group
(HC), UCML, and RCML. They were excluded from further data
analysis because serious outliers negatively affect and thus bias the
Table 1. Information of the CML patients and the health volunteers.
Characteristics HC UCML SCML RCML
Sex Male 9 17 17 8
Female 9 9 2 6
Age (year) Mean6SD 35.269.2 37.6613.4 38.1615.7 39.2614.1
range 18–55 18–67 23–70 18–69
Recent medicine No Hydroxycarbamide Imatinib Imatinib
Duration
of disease
Mean6SD 8.3612.6 17.8624.2 48.5631.6
(months) range 1–33 6–84 6–168
Duration of imatinib Mean6SD 12.2623.3 25.9612.7
treatment (months) range 6–72 6–39
Daily dose (mg) Mean6SD 418652 421677
range 400–600 300–800
doi:10.1371/journal.pone.0013186.t001
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structures and discriminant analysis (PLS–DA) model, the
remaining samples were classified into four groups (HC, UCML,
SCML, and RCML). According to the cross-validation [23], the
PLS–DA model of the three principal components explained
30.8% of the variation in X (R
2X=0.308, GC/TOFMS response
variables/peaks) and 39.7% of the variation in Y (R
2Y=0.397,
sample types), and predicted 23.9% of the sample types. Although
Table 2. Lesion detected in CML samples by SNP array analysis.
Patients
ID Chromosome
Genic
status
Starting
position
Ending
position Genes identified
Disease
status
Response to
imatinib
R01C02 5 Del 81629356 115815122 LOC92270 BC Resistance
R01C02 9 Del 127196469 132665560 FREQ,CDK9 BC Resistance
R01C02 22 Del 22053721 22902745 GSTTP1, LOC388882, IGLL1, C22orf16,
MMP11, SLC2A11, MIF, FLJ31568
BC Resistance
R01C02 22 Dup 23995985 24240879 LRP5L, ADRBK2 BC Resistance
R06C01 7 Del 61862616 61921953 No gene CP Resistance
R06C01 19 Dup 32493654 33528102 LOC727780,LOC642290,LOC727771 CP Resistance
R02C01 11 Del 50354779 51228612 OR4A5, LOC646813 CP Resistance
R02C01 19 Del 20423788 20514068 LOC645490 CP Resistance
R04C01 11 Del 46327343 47374448 F2,SPI1,DGKZ,AMBRA1,MADD
C11orf49,PACSIN3
BC Resistance
R04C01 17 Del 44176361 52843822 .20 genes BC Resistance
R04C01 2 LOH 78822450 89733531 .20 genes BC Resistance
R04C01 2 LOH 98364441 109797238 .20 genes BC Resistance
R04C01 2 LOH 109809150 121111631 .20 genes BC Resistance
R04C01 3 LOH 142389922 153466638 .20 genes BC Resistance
R04C01 5 LOH 156922335 168529461 .20 genes BC Resistance
R04C01 15 LOH 82248349 100215359 .20 genes BC Resistance
R04C01 20 LOH 29310063 55040991 .20 genes BC Resistance
R03C02 1 Del 240744201 241169492 LOC391183, PLD5 CP Sensitivity
Starting position: start position of genomic lesion; Ending position: end position of genomic lesion;LOH: loss of heterozygosity, Del; deletion, Dup; duplication.BC,blast
crisis; CP, chronic-phase.
doi:10.1371/journal.pone.0013186.t002
Figure 1. A typical GC/TOFMS chromatogram of blood plasma. Several hundreds of peaks can be detected at only one analysis and some of
the peaks were identified. Part of the chromatogram was zoomed in for clear inspection of the peaks, 15–19, retention time from 335 to 355 s. 1,
Lactate; 2, butyamine; 3, 3-hydroxybutyrate; 4, valine; 5, urea; 6, phosphate; 7, serine; 8, threonine; 9, pyroglutamate; 10, hydroxyproline; 11,
creatinine; 12, ornithine; 13, phenylalanine; 14, methyl myristate (QC reference standard); 15, glutamine; 16, glycerol-3-phosphate; 17, azelate; 18,
citrate; 19, [
13C2]-myristic acid (stable isotope internal standard); 20, glucose; 21, palmitic acid; 22, uric acid; 23, linoleic acid; 24, oleic acid; 25, stearic
acid; 26, alpha-tocopherol; 27, cholesterol; U1-5, unidentified peaks of retention indices at 1163, 1876, 1986, 2015, 2415, 2448, respectively.
doi:10.1371/journal.pone.0013186.g001
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(Figure 2), obvious separations were observed for HC, SCML, and
UCML. UCML clustered far from SCML and HC, whereas
RCML was scattered and primarily overlapped with UCML,
suggesting that its metabonomic composition was similar to that of
UCML, but different from those of HC and SCML.
A submodel was calculated to further evaluate the metabolic
similarities and differences among SCML, HC, and UCML. The
two-principal-components PLS–DA model (Figure S1) showed
that SCML clustered far from UCML, whereas it overlapped HC,
clearly suggesting that the sensitive metabolome was regulated
towards the normal profile.
Metabonomic differences between UCML patients and
HC
A PLS–DA model between UCML and HC clearly identified
the similarities in the two groups and the significant differences
between the two groups. To better understand the intrinsic
variations, specific compounds were identified. Statistical analysis
(one-way analysis of variance, ANOVA) showed higher levels of
glutamine, myo-inositol, arabinose, glycine, urea, ornithine,
glutamate, pyroglutamate, and an unidentified compound, but
lower levels of citrate, high-density lipoprotein (HDL), linoleate,
and some unidentified peaks in UCML (P,0.05; Table 3). For the
other compounds, such as pipecolate, pseudouridine, urate, a-
tocopherol, adipate, total cholesterol, and nonesterified cholesterol
(free form), the differences between HC and UCML were obvious
but not statistically significant (P.0.05).
Metabolic perturbation of CML after imatinib treatment
To facilitate the identification of the compounds that were
affected by exposure to imatinib, three separate PLS–DA models
were computed between SCML, RCML, and UCML. The first
model between SCML and UCML explained 28.3% of the GC/
TOFMS response variables/peak areas and 74.2% of the sample
types, and also predicted 47.3% of the sample types. The relatively
low capacity to explain the GC/TOFMS response variables
(28.3%) means that the majority of them were not significantly
affected, i.e., not many metabolites were affected in SCML.
Another model between SCML and RCML resulted in a
clustering similar to that of the previous model, suggesting that
metabolic responses to imatinib were evident in these two groups
of patients. However, the model between RCML and UCML
failed to differentiate the two groups according to cross-validation,
which resulted in a negative prediction parameter, Q
2Y, of
210.2%. This means that the metabonomic composition of
RCML was not significantly different from that of UCML. In
summary, in terms of metabonomics, SCML patients differed
from UCML, whereas RCML patients were similar to UCML
patients.
Compared with UCML patients, significant reductions in myo-
inositol, arabinose, pseudouridine, glutamate, and pyroglutamate,
Figure 2. The scores plot of PLS-DA model (3 principal components) of the four groups. UCML, SCML, RCML and the healthy control (HC).
This figure shows the difference between UCML and the healthy control and SCML and UCML, respectively. The overlapping of UCML and RCML
suggested similar metabolic phenotype and indicated the therapeutic ineffectiveness of imatinib on RCML. The overlapping of SCML and HC
suggested similar metabolic phenotype and the therapeutic effectiveness of imatinib on SCML.
doi:10.1371/journal.pone.0013186.g002
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in SCML patients (P,0.05, one-way ANOVA; Table 3). Pipeco-
late, glutamine, glycine, urea, ornithine, citrate, a-tocopherol, and
linoleate levels were also more or less rectified, although not
statistically significantly (P.0.05), but most of them were adjusted
towards normal levels. Interestingly, none of the metabolites listed
in Table 3 were significantly different in RCML and UCML
patients. The results both from the general scores plot (Figure 2)
and for specific compounds (Table 3) confirmed that RCML was
quite similar to UCML.
Metabonomic differences between RCML BC patients
and RCML CP patients
RCML BC patients showed a totally different metabonomic
phenotype from that of RCML CP patients (Figure S2). It is
noteworthy that many compounds, including oleate, palmitate,
linoleate, stearate, glycine, pyroglutamate, arabinose, b-D-methyl-
glucopyranoside, and fumarate, showed significant elevation in
RCML BC patients compared with those in RCML CP patients
(Table S2). Lysine was the only compound occurring at a lower
level in RCML BC patients.
Discussion
Although the correlations between the cytogenetic and
molecular effects and clinical efficacy have been well established,
previous studies have provided little information about the in vivo
metabolism of CML patients during imatinib treatment, except
in terms of bone and mineral metabolism [24], hyperlipidemia
[25], creatine kinase, phosphate, and phosphocholine [26–27].
Hundreds of low-molecular-weight endogenous compounds in
the plasma were profiled here with a high-throughput GC/
TOFMS analysis, and many metabolites that distinguished the
different CML treatment groups were identified. Factors such
as sex, age, background, disease duration, imatinib treatment
duration, and diet can massively affect metabonomics and may
muffle the variation in different groups. Despite these confound-
ing factors,our results notonly showthatUCML differs fromHC
in terms of metabonomics, but also characterize SCML and
RCML, and suggest their similarity to HC and UCML,
respectively. This indicates that metabolic profiling can poten-
tially characterize the status of CML in response to imatinib
(ineffective or effective).
Table 3. The relative abundance of the identified compounds/peaks differentiating UCML from HC and the regulation by imatinib.
Variable Name Healthy control(HC) UCML
Fold
change SCML RCML
Mean ± SD Mean ± SD
UCML/
HC Mean ± SD Mean ± SD
Pipecolate 66738 6 27812 191019 6 150758 2.864 113166 6 69717 164293 6 105135 *
Glutamine 397746 6 178241 731628 6 477666 * 1.839 642994 6 256423 * 744690 6 508088 *
myo-Inositol 2567687 6 1211442 4224531 6 2076166 * 1.645 2460364 6 851377 {{ 3201257 6 2305927
Arabinose 160888 6 54011 263240 6 134590 ** 1.636 169357 6 57379 { 206307 6 106486
Glycine 4994510 6 1934972 7755324 6 3431521 * 1.553 5697956 6 1783735 7589657 6 3502635
Urea
1 (mmol/L) 4.95 6 0.94 7.38 6 1.12 * 1.491 5.10 6 1.21 7.49 6 1.41 *
Ornithine 7051554 6 3092520 10132171 6 3809942 * 1.437 9154095 6 4566462 10755744 6 5278905
Pseudouridine 187540 6 93536 262470 6 132366 1.400 123979 6 55572 { 230273 6 142358
Glutamate 486771 6 129371 672095 6 230155 * 1.381 475953 6 94505 { 591183 6 252764
Pyroglutamate 12872691 6 3860744 17366747 6 3905589 ** 1.349 14246015 6 3677287 { 16553496 6 3610300 *
Urate 8635673 6 5325414 9311846 6 5403118 1.078 11613451 6 3705793 9157485 6 3361998
CPU_ DB5_RI1341_P 66738 6 27812 191019 6 99008 * 2.862 113166 6 69717 164293 6 105135
Citrate 9277095 6 2814476 7138455 6 2012240 * 21.300 8736984 6 1696040 7197272 6 2641511
alpha-Tocopherol 808681 6 165795 601033 6 195359 21.345 683782 6 282667 535638 6 240045 *
Linoleate 8552168 6 3885328 5109234 6 2596822 * 21.400 6439932 6 3154482 5584365 6 3110760
Adipate 202105 6 130022 135086 6 105583 21.495 164819 6 69713 168152 6 82656
HDL
1 (mmol/L) 1.38 6 0.33 0.83 6 0.25 ** 21.663 1.27 6 0.26 { 0.87 6 0.39
Total cholesterol
1
(mmol/L)
4.57 6 1.28 3.28 6 1.03 21.393 3.79 6 0.60 2.76 6 0.77
Non-esterified
cholesterol
66222510 6 11227958 61596173 6 12264833 21.075 59449993 6 10150252 55116351 6 10009437
CPU_ DB5_RI2494_P 4252017 6 1132727 3208128 6 1021383 * 21.325 4008764 6 1149047 { 3019455 6 826266 ** {
CPU_ DB5_RI2664_P 988481 6 549499 648226 6 389483 * 21.525 1080495 6 309271 { 728768 6 315890 {
CPU_ DB5_RI2124_P 177008 6 101696 105477 6 98053 21.678 186469 6 97861 { 110002 6 57932
All peaks areas were normalized by the stable isotope internal standard, [
13C2]-myristic acid; CPU_ DB5_RIx_P: Unidentified compounds in plasma samples detected with
DB-5 capillary column in GC/TOFMS, China Pharmaceutical university (CPU); RI, retention index; x, retention time index value; P, plasma sample.
*,**: statistically significant different from that in HC, p,0.05, 0.01;
{, {{: statistically significant different from that in UCML, p,0.05, 0.01;
{, {{: statistically significant different from that in SCML, p,0.05, 0.01.
1, clinic measurement results.
doi:10.1371/journal.pone.0013186.t003
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HC
The significant metabonomic differences between UCML and
HC indicate metabolic perturbation in CML patients. Of the
metabolites contributing most to the differences between UCML
and HC, intermediates of the tricarboxylic acid (TCA) cycle
(citrate) and lipid metabolism (cholesterol, HDL, linoleate) were
downregulated in UCML, whereas urea cycle metabolites, such as
pyrimidines (pseudouridine), amino acids (glycine, ornithine), and
purines (urate), were elevated to some extent (Table 3, Figure S3).
Consistent with the results for other tumors [16,28], some amino
acids, such as glutamate, ornithine, glycine, and pyroglutamate,
were found at higher levels in UCML compared with those in HC,
which indicates a cellular requirement for a higher turnover of
structural proteins. Purines (urate) were detected at higher levels in
UCML, indicative of a higher capacity for DNA synthesis. After
the imatinib intervention, we detected a higher level of urate in
SCML than in UCML, which is supported by a previous report
[27]. The relatively lower level of citrate suggests the downreg-
ulation of the TCA cycle and that CML cells require higher-
energy metabolism. This is achieved through the upregulation of
amino acid transporters, cellular molecule synthesis, and signal
transduction by the delivery of carbon backbones. Increased
glycolysis has been consistently observed in cancer cells [28,29],
but whether this metabolic shift is a consequence or cause of
cancer remains controversial [30].
Metabonomic differences between SCML and RCML
After imatinib treatment, SCML patients underwent an obvious
metabolic perturbation, whereas RCML patients were not
significantly affected. The relevant changes in regulatory path-
ways, in response to the drug intervention, can be discerned from
the discrete transcriptomic and metabonomic datasets [31]. Based
on our metabonomic results, both the mathematical PLS–DA
model and the suggested markers offer alternative diagnostic
methods to cytogenetics.
To evaluate the genomic effect on metabolic phenotype, SNP
array analysis was applied to identify the difference between CP &
BC CML, and SCML & RCML. Our data are consistent with a
recent SNP array study that submicroscopic alterations were
detectable on chromosome 1,9,17 and 22 [32]. Deletions,
duplication and LOH on chromosome 17, 9, 22, 5 and 19 were
identified in several important chromosomal regions of BC
patients. Chromosome 17 was most heavily affected by secondary
genomic alterations on development of TKI resistance during
disease progression [32,33]. The deletions and amplifications on
chromosomes 9 and 22, which were suggested to be associated
with TKI resistance or disease progression [32], were detectable in
1 secondary resistant sample developing imatinib resistance. In
contrast to the lesions on chromosome 17, 9 and 22, chromosome
1 may be involved in the initial development of CML rather than
associated with TKI resistance [32], just as one of SCML patients
showed deletion on chromosome 1 (Table 2).
Of the 14 RCML patients, only one BC patients carried ABL
kinase domain mutations, so the different metabolic phenotypes of
RCML and SCML are not necessarily dependent on ABL domain
mutations. The difference is probably attributable to the activation
of other pathways for the survival and proliferation of CML cells
[34]. On the other hand, deletion or duplication on chromosome
1, 11 or 22, may lead to abnormal expression of genes which are
all involved in cell lipid metabolism, including PLD5, LRP5L and
AMBRA1. One of the genes in this deleted region on chromosome
22 was SLC2A11, a class II sugar transport facilitator, which
exhibits highest similarity with the fructose transporter GLUT5.
Three studies have reported expression signatures of CD34+ cells
in relation to CML blast crisis and duration of chronic phase in
patients treated with nonimatinib or imatinib therapy, respectively
[35,36,37]. Comparison with both the Zheng et al.[35] and Yong
et al [36] data, McWeeney et al.[37] found five genes (CSTA,
RNASE3, PRTN3, PLAUR, and MPO) overlapped between the 3
datasets. Unfortunately, we failed to associate the metabolic data
and the published genomic data.
The metabonomic data (Table S2) indicate that BC cells
maintain a highly glycolytic status, with increased glucose and
urate production, and require more source materials (such as
amino acids and lipids) to support cell proliferation. Taken
together, it strongly suggested that metabolic variation between
BC and CP patients were closely related to genomic alterations.
Conversely, as in other solid cancer cells, the leukemia cells
exhibited increased glycolysis, and took advantage of this
metabolic pathway for ATP generation as a main source of
energy. This phenomenon is known as the ‘‘Warburg effect’’ and is
considered one of the most fundamental metabolic changes that
occur during malignant transformation [28,29,38]. Imatinib
reverses the Warburg effect in BCR–ABL-positive cells by
switching from glycolysis to mitochondrial glucose metabolism,
resulting in a reduction in glucose uptake and a higher energy state
[38]. The metabolic phenotype of SCML showed modification of
the TCA cycle and lipid metabolism, together with the upregula-
tion of de novo nucleotide triphosphate/deoxynucleotide triphos-
phate synthesis [38]. In accordance with a previous study, these
results suggest that imatinib exerts its effect by arresting DNA
replication and the cell-proliferation cycle [11].
In this study, both HDL and total cholesterol decreased in
RCML and increased in SCML. Cholesterol is an integral
component of all eukaryotic cell membranes and is essential for
normal cellular function. It is well known that the major function
of HDL is to maintain cholesterol homeostasis in normal cells
through the removal of excess cholesterol from intracellular pools.
Plasma HDL concentrations reflect the activity of a number of
intra- and extracellular metabolic pathways. The plasma levels of
this lipoprotein can be determined by the flow of cholesterol
through the extracellular pathways [39]. A reduction in HDL
correlates with the accumulation of cholesterol esters during cell
proliferation [40]. We presume that the low level of HDL observed
in our study was associated with increasing BCR–ABL-mediated
cell proliferation and a resistance to imatinib in vivo.
Metabonomic differences between SCML and HC
The modification of the metabolome and the genome occurred
synchronously during effective treatment with imatinib, followed
by a reduction in the burden of CML cells. The metabolic
phenotype of SCML was similar to that of HC, but the two groups
did not completely overlap, even after years of treatment with
imatinib. This result reinforces the observation that SCML
patients are in fact genetically different from HC patients. We
postulate three reasons why the metabolomes of SCML patients
did not completely overlap those of HC. First, although the active
CML cells that were sensitive to imatinib shifted towards a normal
metabolism, quiescent and residual CML cells may influence the
biochemical networks [41]. Second, besides its positive effect on
CML, imatinib may affect other metabolic pathways. For
example, Rowley proposed that imatinib treatment potentially
targets the BCR–ABL fusion gene but may disrupt critical pathways
required for normal cell function [42]. Third, many patients who
were translocation negative in a standard cytogenetic analysis
showed very low amounts of the BCR–ABL fusion on reverse
transcriptase–polymerase chain reaction (PCR) analysis [6].
Drug Responses in CML Patients
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normal karyotype, still maintain a diseased status.
In summary, our results not only identify metabonomic
differences between UCML and HC, but also demonstrate and
correlate the genetic and metabolic responses to the imatinib
intervention. Therefore, the metabonomic profiling described here
may be useful for monitoring the metabolic changes that occur
following imatinib treatment of CML. The analysis of metabolic
changes may also be used as an alternative method of
characterizing individual responses to imatinib in a population
of CML patients, which may ultimately lead to personalized
therapeutic strategies. This study opens the way to the identifica-
tion of gene-to-metabolite networks, and offers a method for the
early prediction of responsiveness to imatinib and the personal-
ization of treatment, thus improving clinical and therapeutic
decisions.
Materials and Methods
Chemicals
All the authentic reference standards and reagents were of
analytical, silylation, or chromatography grades, and were
purchased from Sigma-Aldrich (St Louis, MO, USA), Merck
(Darmstadt, Germany), Fluka (Buchs, Switzerland), Aldrich
(Steinhein, Germany), Serva (Heidelberg, Germany), Sigma-
Aldrich (Isotec, USA), and Pierce Chemical Company (USA).
Distilled water was produced with a Milli-Q Reagent Water
System (Millipore, MA, USA).
Patients and plasma samples
Fifty-nine male and female individuals attending Jiangsu
Province Hospital, aged 18 years or older, were eligible for
inclusion if they had been diagnosed with CML between January
2007 and September 2008. Of these patients, 26 were untreated or
were treated with hydroxycarbamide, and were designated
‘‘untreated CML’’ (UCML), and 33 were treated with 300–
800 mg/d imatinib. Eighteen healthy adult volunteers with no
genetic, hepatic, renal, or cardiovascular disease were selected by
matching them in age and sex to the CML patients. Diet, weight,
and levels of physical activity remained unchanged during the
course of the imatinib therapy. All the patients and healthy
volunteers provided their written informed consent before
enrollment in the study. The study was approved by the
Institutional Review Board of the Nanjing Medical University.
Cytogenetic analysis
Bone marrow was obtained from the patients. The karyotypes
were evaluated with an R-banded analysis of 20 metaphase cells
from unstimulated, cultured (24 h) bone-marrow aspirates. The
karyotypes were described according to the international system
for human cytogenetic nomenclature guidelines [43]. Chronic-
phase, blast crisis, and primary cytogenetic resistance were as
defined in recent studies [5,6].
Analysis of mutations in the ABL kinase domain
DNA was extracted from peripheral blood or bone marrow
samples with a standard phenol/chloroform extraction method.
The primer pairs were designed with primer3 software (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) to amplify
the coding sequence of ABL (Table S3). The ABL kinase domain of
the BCR–ABL allele was amplified with a PCR–restriction
fragment length polymorphism technique, followed by direct
sequencing and sequence homology analysis. Sequencing was
performed with the BigDye Terminator Cycle Sequencing Ready
Reaction Kit (PerkinElmer BioSystems, Foster City, CA, USA) on
an ABI Prism 3700 DNA Analyzer (PerkinElmer BioSystems).
SNP array analysis
Genomic DNA isolated from cells was subjected to GeneChip
Human mapping microarray (Shanghai SNP-chip, Illumina,Inc,
CA, USA). High-quality genomic DNA was processed in
accordance with the genomic mapping 250K NspI protocol and
hybridized to 250K NspI SNP arrays according to the manufac-
turer’s instructions. Data analysis of deletions, amplifications and
loss of heterozygosity (LOH) was carried out using the CNAG
(copy number analysis for Affymetrix GeneChips)software with
nonmatched references.
Sample preparation and GC/TOFMS analysis
Plasma was isolated and treated as previously reported [22],
with a few modifications. Briefly, 100 mL of plasma was thawed,
400 mL of methanol was added to the extract, and the protein was
precipitated. [1,2-
13C2]-Myristic acid (2 mg) was added as the
internal standard. The supernatant (100 mL) was dried, methoxi-
mated, trimethylsilylated, and prepared for analysis. To extract
more information from the study, triglyceride (TC), urea, total
cholesterol (TG), and high- and low-density lipoproteins (HDL
and LDL, respectively) were determined with an automatic
biochemical analyzer (Olympus AU5400, Japan) at Nanjing
Medical University.
To minimize the systematic variation, all plasma samples were
randomly analyzed by GC/TOFMS using a previously reported
method [22]. To achieve better chromatographic separation, the
column temperature was initially maintained at 70uC for 2 min,
and then increased at a rate of 35uC/min from 70uC to 305uC,
where it was maintained for 2 min. Masses were scanned and the
data were acquired from m/z 50–800 at a rate of 30 spectra/s.
Data processing and pattern recognition
Automatic peak detection and mass spectrum deconvolution
were performed with the ChromaTOF
TM software (version 3.25)
and the peak areas were obtained as reported previously [21]. A
data matrix of the peak areas was thus constructed, with the
observation/samples in the first column and the responses/peaks
as variables in the first row. The retention index was calculated by
comparing the retention times of the peaks with those of the alkane
series C8–C40. The compounds were identified by the comparison
of the mass spectra and retention indices of all the detected peaks
with authentic reference standards available in the National
Institute of Standards and Technology library 2.0 (2005) and an
in-house mass spectra library database maintained by Umea Plant
Sciences Center, Sweden.
Pattern recognition was performed with the professional data
processing software SIMCA-P 11 (Umetrics, Umea ˚, Sweden).
PCA and PLS–DA were used to analyze the data with a standard
method [44]. The statistical results of the normalized peak areas
were validated with one-way ANOVA.
Supporting Information
Figure S1 The PLS_DA scores plot of SCML, UCML and
healthy control (HC). The overlapping of SCML and HC
suggested the rectification of endogenous compound in SCML
towards normal. While the distinct separation of SCML and
UCML suggested metabolic responses to imatinib.
Found at: doi:10.1371/journal.pone.0013186.s001 (0.32 MB
TIF)
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and RCML CP (%, n=8) patients. RCML BC patients showed
totally different metabonomic phenotype from that of RCML CP
patients.
Found at: doi:10.1371/journal.pone.0013186.s002 (0.16 MB TIF)
Figure S3 Metabolic perturbations in UCML and metabolic
response to imatinib treatment. The marked metabolites were
observed at an abnormal level in UCML, and most of them were
regulated towards normal in SCML with imatinib. Red or green
blocks represent a statistically significant higher or lower
level(p,0.05, one-way ANOVA) in UCML in comparison with
the healthy control, respectively. Pink and blue blocks represent a
higher or lower (not statistical significance, p.0.05, one-way
ANOVA) level in UCML in comparison with healthy control,
respectively.
Found at: doi:10.1371/journal.pone.0013186.s003 (0.20 MB TIF)
Table S1 Compounds identified in human blood plasma.
Found at: doi:10.1371/journal.pone.0013186.s004 (0.12 MB
DOC)
Table S2 The relative abundance of the identified compounds/
peaks differentiating RCML BC from RCML CP patients.
Found at: doi:10.1371/journal.pone.0013186.s005 (0.06 MB
DOC)
Table S3 Primer pairs used for PCR.
Found at: doi:10.1371/journal.pone.0013186.s006 (0.04 MB
DOC)
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